MZE829

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biotech company translating human genetic insights into novel precision medicines for genetically defined diseases. Founded in 2018 and publicly traded, its core strategy leverages its proprietary Compass Platform to identify protective genetic variants as a blueprint for drug development. Key achievements include building a focused pipeline led by MZE829 for APOL1-mediated kidney disease, with promising Phase 2 proof-of-concept data recently reported, and advancing a GLP-1 agonist for obesity. The company's approach aims to de-risk drug discovery by targeting pathways with direct human genetic validation.

Therapeutic Areas